NasdaqGS:NVCRMedical Equipment
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile
NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax in locally advanced pancreatic cancer and has started commercial launch.
The approval extends the company’s Tumor Treating Fields technology beyond its historic focus in glioblastoma into a new oncology market.
NovoCure also announced a new CEO and a reorganization of its clinical team alongside the launch.
NovoCure now trades around $13.67, with the stock up 20.3% over the past week and 8.7% over the past month, while longer...